Breaking News, Collaborations & Alliances

GSK Bids for Human Genome Sciences

HGS rejects $2.6 billion offer from Benlysta partner

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

GlaxoSmithKline has made an offer to acquire Human Genome Sciences for $2.6 billion in cash. The price reflects an 81% premium to the last closing price of the stock. HGS’ board rejected the initial offer, and is seeking strategic alternatives. GSK and HGS collaborated on Benlysta, which was recently approved by the FDA to treat lupus. The companies are also working on other projects, including darapladib, a heart treatment currently in Phase III. GSK and HGS currently split Benlysta reve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters